Department of Internal Medicine, Third Faculty of Medicine, Charles University, and Královské Vinohrady University Hospital, Prague, Czech Republic.
Institute for Biometrics and Epidemiology, German Diabetes Center (Deutsches Diabetes-Zentrum/DDZ), Leibniz Center for Diabetes Research at Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
Nutr Diabetes. 2023 Jul 17;13(1):11. doi: 10.1038/s41387-023-00241-7.
COVID-19, an infectious disease caused by SARS-CoV-2, was shown to be associated with an increased risk of new-onset diabetes. Mechanisms contributing to the development of hyperglycemia are still unclear. We aimed to study whether hyperglycemia is related to insulin resistance and/or beta cell dysfunction.
Survivors of severe COVID-19 but without a known history of diabetes were examined at baseline (T0) and after 3 (T3) and 6 (T6) months: corticosteroids use, indirect calorimetry, and OGTT. Insulin response and sensitivity (IS) were expressed as insulinogenic (IGI), disposition (DI), and Matsuda insulin sensitivity index (ISI). Resting energy expenditure (REE) and respiratory quotient (RQ) was calculated from the gas exchange and nitrogen losses.
26 patients (out of 37) with complete outcome data were included in the analysis (age ~59.0 years; BMI ~ 30.4, 35% women). Patients were hypermetabolic at T0 (30.3 ± 4.0 kcal/kg lean mass/day, ~120% predicted) but REE declined over 6 months (ΔT6-T0 mean dif. T6-T0 (95% CI): -5.4 (-6.8, -4.1) kcal/kg FFM/day, p < 0.0001). 17 patients at T0 and 13 patients at T6 had hyperglycemia. None of the patients had positive islet autoantibodies. Insulin sensitivity in T0 was similarly low in hyperglycemic (H) and normoglycemic patients (N) (T0 ISI = 3.12 ± 1.23, ISI = 3.47 ± 1.78, p = 0.44), whereas insulin response was lower in the H group (DI = 3.05 ± 1.79 vs DI = 8.40 ± 5.42, p = 0.003). Over 6 months ISI (ΔT6-T0 mean dif. T6-T0 for ISI (95% CI): 1.84 (0.45, 3.24), p = 0.01)) increased in the H group only.
Patients with severe COVID-19 had increased REE and insulin resistance during the acute phase due to the infection and corticosteroid use, but these effects do not persist during the follow-up period. Only patients with insufficient insulin response developed hyperglycemia, indicating that beta cell dysfunction, rather than insulin resistance, was responsible for its occurrence.
由 SARS-CoV-2 引起的传染性疾病 COVID-19 被证明与新发糖尿病的风险增加有关。导致高血糖的机制仍不清楚。我们旨在研究高血糖是否与胰岛素抵抗和/或β细胞功能障碍有关。
在基线(T0)以及 3 个月(T3)和 6 个月(T6)时,检查患有严重 COVID-19 但无已知糖尿病史的幸存者:皮质类固醇的使用、间接热量测定和 OGTT。胰岛素反应和敏感性(IS)表示为胰岛素原(IGI)、处置(DI)和 Matsuda 胰岛素敏感性指数(ISI)。静息能量消耗(REE)和呼吸商(RQ)是从气体交换和氮损失中计算得出的。
26 名(37 名中的 26 名)患者具有完整的结果数据被纳入分析(年龄59.0 岁;BMI30.4,35%女性)。患者在 T0 时处于高代谢状态(30.3±4.0 kcal/kg 去脂体重/天,约 120%预测值),但 REE 在 6 个月内下降(ΔT6-T0 均值差异 T6-T0(95%CI):-5.4(-6.8,-4.1)kcal/kg FFM/天,p<0.0001)。在 T0 时,有 17 名患者和在 T6 时有 13 名患者出现高血糖。无患者有阳性胰岛自身抗体。在 T0 时,高血糖(H)和血糖正常(N)患者的胰岛素敏感性相似(T0 ISI=3.12±1.23,ISI=3.47±1.78,p=0.44),而 H 组的胰岛素反应较低(DI=3.05±1.79 vs DI=8.40±5.42,p=0.003)。在 6 个月内,H 组的 ISI(T6-T0 均值差异 T6-T0 的 ISI(95%CI):1.84(0.45,3.24),p=0.01))仅增加。
患有严重 COVID-19 的患者在感染和皮质类固醇使用期间急性期会出现 REE 和胰岛素抵抗增加,但在随访期间这些影响不会持续存在。只有胰岛素反应不足的患者才会出现高血糖,这表明β细胞功能障碍而不是胰岛素抵抗是其发生的原因。